# US 2018/0002426 A1 · Stabilized Formulations Containing Anti-Interleukin-4 Receptor (IL-4R) Antibodies

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2018/0002426 A1
- Document ID: US20180002426A1
- Status: Published application
- Kind: A1
- Application number: 15/424,578
- Filed: 2017-02-03
- Published: 2018-01-04
- Earliest claimed: 2010-10-06
- Assignees: Regeneron Pharmaceuticals, Inc.
- Applicants: Regeneron Pharmaceuticals, Inc.
- Inventors: Daniel B. Dix; Xiaolin Tang
- Web page: https://patentgrep.com/patent/US20180002426A1

## CPC

- C07K 16/2866: {against receptors for cytokines, lymphokines, interferons}
- A61K 9/0019: {Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner (non-active ingredients are additionally classified in A61K47/00)}
- A61K 39/39591: {Stabilisation, fragmentation}
- A61K 47/183: {Amino acids, e.g. glycine, EDTA or aspartame}
- A61M 5/315: Pistons; Piston-rods; Guiding, blocking or restricting the movement of the rod {or piston}; Appliances on the rod for facilitating dosing {; Dosing mechanisms}
- A61P 11/06: Antiasthmatics
- A61P 17/00: Drugs for dermatological disorders
- A61P 17/04: Antipruritics
- A61P 27/14: Decongestants or antiallergics
- A61P 29/00: Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A61P 37/08: Antiallergic agents (antiasthmatic agents A61P11/06; ophthalmic antiallergics A61P27/14)
- C07K 2317/21: from primates, e.g. man
- C07K 2317/56: variable (Fv) region, i.e. VH and/or VL
- C07K 2317/94: Stability, e.g. half-life, pH, temperature or enzyme-resistance
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61M: DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY (introducing media into or onto the bodies of animals A61D7/00; means for inserting tampons A61F13/26; devices for administering food or medicines orally A61J; containers for collecting, storing or administering blood or medical fluids A61J1/05); DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY (surgery A61B; chemical aspects of surgical articles A61L); DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR {(Electrotherapy, e.g. producing anaesthesia by the use of alternating or intermittent currents A61N1/36021)}
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

The present invention provides pharmaceutical formulations comprising a human antibody that specifically binds to human interleukin-4 receptor (hIL-4R). The formulations may contain, in addition to an anti-hIL-4R antibody, at least one amino acid, at least one sugar, or at least one non-ionic surfactant. The pharmaceutical formulations of the present invention exhibit a substantial degree of antibody stability after storage for several months.

## Claims

### Claim at position 1

1-29. (canceled)

### Claim 30

A stable pharmaceutical formulation comprising:
(i) a human antibody that specifically binds to human interleukin-4 receptor alpha (hIL-4Rα) and comprises a heavy chain variable region comprising the amino acid sequence of SEQ ID NO:1 and a light chain variable region comprising the amino acid sequence of SEQ ID NO:5;
(ii) acetate at a concentration of from 10 mM to 15 mM;
(iii) histidine at a concentration of from 15 mM to 25 mM;
(iv) sucrose at a concentration of from 2.5% w/v to 10% w/v;
(v) polysorbate at a concentration of from 0.1% w/v to 0.3% w/v; and
(vi) arginine at a concentration of from 20 mM to 100 mM,
wherein the formulation has a pH of from 5.6 to 6.2.

### Claim 31 (depends on 30)

The pharmaceutical formulation of claim 30, wherein the acetate is present at a concentration of 12.5 mM±1.85 mM and the histidine is present at a concentration of 20 mM±0.3 mM.

### Claim 32 (depends on 30)

The pharmaceutical formulation of claim 30, wherein the polysorbate is polysorbate 20, or polysorbate 80.

### Claim 33 (depends on 32)

The pharmaceutical formulation of claim 32, wherein the polysorbate is polysorbate 20 at a concentration of 0.2%±0.03% w/v.

### Claim 34 (depends on 32)

The pharmaceutical formulation of claim 32, wherein the polysorbate is polysorbate 80 at a concentration of 0.2%±0.03% w/v.

### Claim 35 (depends on 30)

The pharmaceutical formulation of claim 30, wherein the sucrose is present at a concentration of 5%±0.75% w/v.

### Claim 36 (depends on 30)

The pharmaceutical formulation of claim 30, wherein the arginine is present at a concentration of 25 mM±3.75 mM.

### Claim 37 (depends on 30)

The pharmaceutical formulation of claim 30, wherein the arginine is present at a concentration of 50 mM±7.5 mM.

### Claim 38 (depends on 30)

The pharmaceutical formulation of claim 30, wherein the viscosity of the liquid is 11±1.1 cPoise or 8.5±0.85 cPoise.

### Claim 39 (depends on 30)

The pharmaceutical formulation of claim 30, wherein the osmolality of the liquid is 290±20 mOsm/kg.

### Claim 40 (depends on 30)

The pharmaceutical formulation of claim 30, wherein:
(a) at least about 98% of the native form of the antibody is recovered after about six months of storage at about 5° C., as determined by size exclusion chromatography;
(b) at least about 90% of the native form of the antibody is recovered after about eight weeks of storage at about 45° C., as determined by size exclusion chromatography;
(c) less than about 45% of the antibody recovered after about eight weeks of storage at about 45° C. is an acidic form, as determined by cation exchange chromatography; or
(d) less than about 4% of the antibody recovered after six months of storage at 25° C. is aggregated, as determined by size exclusion exchange chromatography.

### Claim 41 (depends on 30)

The pharmaceutical formulation of claim 30, wherein the pharmaceutical formulation is contained in a glass vial.

### Claim 42 (depends on 30)

The pharmaceutical formulation of claim 30, wherein the pharmaceutical formulation is contained in a syringe.

### Claim 43 (depends on 30)

The pharmaceutical composition of claim 30, wherein the pharmaceutical composition is contained in a prefilled syringe.

### Claim 44 (depends on 30)

The pharmaceutical composition of claim 30, wherein the pharmaceutical composition is contained in an autoinjector.

### Claim 45 (depends on 30)

The pharmaceutical formulation of claim 30, wherein the pharmaceutical formulation is contained in a microinfusor.

### Claim 46 (depends on 42)

The pharmaceutical formulation of claim 42, wherein the syringe comprises a fluorocarbon-coated plunger.

### Claim 47 (depends on 42)

The pharmaceutical formulation of claim 42, wherein the syringe is a low tungsten syringe.

### Claim 48

A stable pharmaceutical formulation comprising:
(i) a human antibody at a concentration of from 15 mg/ml to 200 mg/ml, wherein the antibody specifically binds to hIL-4Rα, and comprises a heavy chain and light chain variable region (HCVR/LCVR) amino acid sequence pair of SEQ ID NOs:1/5;
(ii) 12.5 mM±2 mM acetate;
(iii) 20 mM±3 mM histidine;
(iv) 5%±0.75% sucrose;
(v) 0.2%±0.03% polysorbate 20; and
(vi) 25 mM±3.75 mM arginine,
at a pH of 5.9±0.5.

### Claim 49 (depends on 48)

The pharmaceutical formulation of claim 48, wherein the viscosity of the liquid is 11±1.1 cPoise or 8.5±0.85 cPoise, and the osmolality of the liquid is 290±20 mOsm/kg.

### Claim 50 (depends on 48)

The pharmaceutical formulation of claim 48, wherein:
(a) at least about 98% of the native form of the antibody is recovered after six months of storage at 5° C., as determined by size exclusion chromatography;
(b) at least about 90% of the native form of the antibody is recovered after eight weeks of storage at 45° C., as determined by size exclusion chromatography;
(c) less than about 45% of the antibody recovered after eight weeks of storage at 45° C. is an acidic form, as determined by cation exchange chromatography; or
(d) less than about 4% of the antibody recovered after six months of storage at 25° C. is aggregated, as determined by size exclusion exchange chromatography.

### Claim 51

A stable pharmaceutical formulation comprising:
(i) a human antibody at a concentration of from 15 mg/ml to 200 mg/ml, wherein the antibody specifically binds to hIL-4Rα, and comprises a heavy chain and light chain variable region (HCVR/LCVR) amino acid sequence pair of SEQ ID NOs:1/5;
(ii) 12.5 mM±2 mM acetate;
(iii) 20 mM±3 mM histidine;
(iv) 5%±0.75% sucrose;
(v) 0.2%±0.03% polysorbate 80; and
(vi) 50 mM±3.75 mM arginine,
at a pH of 5.9±0.5.

### Claim 52

A stable pharmaceutical formulation comprising:
(i) a human antibody at a concentration of from 15 mg/ml to 200 mg/ml, wherein the antibody specifically binds to hIL-4Rα, and comprises a heavy chain and light chain variable region (HCVR/LCVR) amino acid sequence pair of SEQ ID NOs:1/5;
(ii) 12.5 mM±2 mM acetate;
(iii) 20 mM±3 mM histidine;
(iv) 5%±0.75% sucrose;
(v) 0.2%±0.03% polysorbate 80; and
(vi) 25 mM±3.75 mM arginine,
at a pH of 5.9±0.5.
